Janet Woodcock, Paul Kim join Friends’ board of directors

Beyond the $500B Stargate Project: The frontier of AI in oncology beckons

On Jan. 21, President Donald Trump announced the launch of the Stargate Project, a $500 billion artificial intelligence infrastructure project designed to revolutionize healthcare.

January 24, 2025

Vol.51 No.03

By Sorena Nadaf-Rahrov

In Brief

University Hospitals and Case Western Reserve fund magnetic resonance fingerprinting research

The Collaborative Science Pilot Awards, a program supported by the Case Western Reserve University—University Hospitals Joint Strategic Leadership Committee, awarded five research teams $50,000 with the possibility of receiving additional funding as scientific milestones are met.

January 24, 2025

Vol.51 No.03

Clinical Roundup

Deadly dog cancer reveals clues for improved treatment, UF study finds

Researchers at the University of Florida College of Veterinary Medicine and the UF Health Cancer Center have identified a crucial link between a gene mutation and immune system signaling in canine hemangiosarcoma, a discovery that could lead to better treatments for both dogs and humans with similar cancers.

January 24, 2025

Vol.51 No.03

Drugs & Targets

FDA grants RP1 BLA priority review for advanced melanoma

FDA has accepted the Biologics License Application from Replimune Group Inc. for RP1 (vusolimogene oderparepvec) in combination with nivolumab (Opdivo) for patients with advanced melanoma.

January 24, 2025

Vol.51 No.03

Guest Editorial

FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials

The U.S. Food and Drug Administration and the U.S. Department of Health and Human Services Office of Human Research Protections issued Draft Guidance on the inclusion of tissue biopsies in clinical trials.

January 17, 2025

Vol.51 No.02

By Laura A. Levit, Mark J. Ratain, Julie R. Gralow, Clifford A. Hudis and Elizabeth Garrett-Mayer

Drugs & Targets

FDA approves sotorasib + panitumumab for KRAS G12C-mutated colorectal cancer

FDA approved sotorasib (Lumakras) with panitumumab (Vectibix) for adult patients with KRAS G12C-mutated metastatic colorectal cancer, as determined by an FDA-approved test, who have received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

January 17, 2025

Vol.51 No.02

Janet Woodcock, Paul Kim join Friends’ board of directors

YOU MAY BE INTERESTED IN

Beyond the $500B Stargate Project: The frontier of AI in oncology beckons

University Hospitals and Case Western Reserve fund magnetic resonance fingerprinting research

Deadly dog cancer reveals clues for improved treatment, UF study finds

FDA grants RP1 BLA priority review for advanced melanoma

FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials

FDA approves sotorasib + panitumumab for KRAS G12C-mutated colorectal cancer

Renew today!

Subscriber content

Never miss an issue!

Login